JURO SCIENCE Inc. is conducting research and development of SFG-02, a preclinical candidate for the treatment of underactive bladder (UAB), a condition characterised by impaired bladder voiding function and residual urine due to ageing or central and peripheral nervous system disorders.

They have in-licensed SFG-002, a compound that had progressed to a Phase IIa clinical trial at Takeda Pharmaceutical Company, and are developing it as a novel therapeutic agent for UAB with a new formulation and clinical development strategy.

We offer early disease diagnosis services based on gene expression analysis technology primarily using RNA derived from blood.
Our main services include the manufacture and sale of the pancreatic cancer test kit “PanRegza® (Approval Number 30400EZX00046000)” and contract analysis services.

The company is engaged in research and development aimed at advancing mobility technologies, and is involved in the manufacturing and sales of products related to advanced mobility systems.

A medical venture focused on developing program-based medical devices using uniquely analyzed vital data.
Currently developing a diabetes treatment app called “glucose flight,” which features AI-powered automatic blood glucose level prediction for patients with type 2 diabetes.
Our mission is to “design next-generation treatments with digital therapeutics.”